Literature DB >> 9723329

Pirfenidone: a novel antifibrotic agent with implications for the treatment of obliterative bronchiolitis.

A K Dosanjh1, B Wan, W Throndset, S Sherwood, R E Morris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9723329     DOI： 10.1016/s0041-1345(98)00478-3

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

1.  Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.

Authors:  Gary A Visner; Fengzhi Liu; Peyman Bizargity; Hanzhong Liu; Kaifeng Liu; Jun Yang; Liqing Wang; Wayne W Hancock
Journal:  Transplantation       Date:  2009-08-15       Impact factor: 4.939

Review 2.  Immunosuppression in lung transplantation.

Authors:  Jenna L Scheffert; Kashif Raza
Journal:  J Thorac Dis       Date:  2014-08       Impact factor: 2.895

3.  In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.

Authors:  Qiang Shi; Xiaoyan Liu; Yuanyuan Bai; Chuanjue Cui; Jun Li; Yishi Li; Shengshou Hu; Yingjie Wei
Journal:  PLoS One       Date:  2011-11-23       Impact factor: 3.240

4.  The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.

Authors:  Melanie Mediavilla-Varela; Kingsley Boateng; David Noyes; Scott J Antonia
Journal:  BMC Cancer       Date:  2016-03-02       Impact factor: 4.430
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.